As expected, an FDA panel voted in favor of giving Dexcom’s ($DXCM) G5 continuous glucose monitor a nonadjunctive indication that would allow it to be used in place ...
The FDA has signed off on the use of DexCom's (NASDAQ:DXCM +2.9%) G5 Continuous Glucose Monitoring System to make diabetes treatment decisions in patients at least two years old without the need for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback